Week 1- Fatty liver disease Flashcards
Criteria for NAFLD
hepatic steatosis (fat) and exclusion of secondary causes (i.e. alcohol, medication, hereditary disorders)
steatosis
abnormal retention of fat (lipids) within an organ
hepatic steatosis
fat accumulation in the liver
hepatitis
inflammation of the liver
steatohepatitis
fat accumulation and inflammation of the liver (steatosis + hepatitis)
fibrosis
scarring
progression of NAFLD
simple steatosis/ NAFL –> non-alcoholic steatohepatitis (NASH) –> NASH with fibrosis or NASH with cirrhosis –> NASH with hepatocellular carcinoma
cirrhosis
permanent liver damage (scar tissue replaces liver cells)
what % of hepatic steatosis is need for NAFLD and NASH
> 5%
prevalence of NAFLD
20% CAD, 37% USA
prevalence of NASH
5%
average age of NAFLD diagnosis
50 yrs (childhood rate is rising bc of obesity)
race effected by NAFLD most
- Hispanics > Caucasians > African Americans
- In Caucasians, men > women (but no sex difference in Hispanics and African-Americans)
3 risk factors of NAFLD
- obesity
- diabetes mellitus
- dyslipidemia/hypertriglyceridemia
AKA insulin resistance and metabolic syndrome
metabolic syndrome criteria
3/5
-blood pressure elevated
-fasting glucose level
-HDL cholesterol
-triglyceride level
-waist circumference >
MAFLD
metabolic associated fatty liver disease
maternal risk factors of NAFLD
maternal obesity and high maternal early pregnancy glucose concentrations
maternal protective factors for NAFLD
breastfeeding >6 months (reduces risk in mom and offspring)
risk factors and causes of NAFLD
-drugs (i.e. corticosteroids)
-toxins (i.e. vinyl chloride)
-diet (fructose, malnutrition, starvation and referring, total parenteral nutrition ie IV feeding)
-genetic factors
genetic polymorphisms at risk for NAFLD
- Polymorphisms of the gene encoding apolipoprotein C3
- Polymorphisms of the patatin-like phospholipase domain- containing 3 (PNPLA3) gene
- Polymorphism of TM6SF2
- Variants of MBOAT1 and GCKR
- Polymorphism of HSD17B13 is protective
associated conditions with NAFLD
- Cushing syndrome
- Hypopituitarism
- Polycystic ovarian syndrome
- Hypothyroidism
- Hypobetalipoproteinemia (low apolipoprotein B and LDL cholesterol)
- Obstructive sleep apnea
- Gut dysbiosis
- Altered bile acid metabolism
- Cholecystectomy
- Psoriasis
NAFLD clinical course
slow progression (i.e. 10 years), reversible (when NAFLD, not NASH if cirrhosis present, NASH with fibrosis is reversible)
NAFL –> 20% NASH –> 20% cirrhosis –> liver failure or cancer
symptoms of NAFLD
asymptomatic
fatigue, malaise, mild RUQ pain
advanced stages of NAFLD symptoms
nausea, vomit, jaundice, pruritis, memory impaired, easy bleeding, loss of appetite, hepatomegaly,
spider angiomas (blood vessels on skin), portal hypertension (edema, ascites, caput medusae - network of veins of abdomen), palmar erythema, gynecomastia (man boobs from excess estrogen), petechiae